Skip to main content Back to Top
Advertisement

5/22/2019

Methylphenidate Extended-Release Oral Suspension and Chewable Tablets

Reason for the Shortage

    • Tris Pharma has Quillivant XR oral suspension and QuilliChew ER chewable tablets available.

Available Products

    • QuilliChews chewable tablet, Tris Pharma, 20 mg, bottle, 100 count, NDC 24478-0074-01
    • QuilliChews chewable tablet, Tris Pharma, 30 mg, bottle, 100 count, NDC 24478-0075-01
    • QuilliChews chewable tablet, Tris Pharma, 40 mg, bottle, 100 count, NDC 24478-0076-01
    • Quillivant XR oral powder for suspension, Tris Pharma, 5 mg/mL, 120 mL bottle, NDC 24478-0322-04
    • Quillivant XR oral powder for suspension, Tris Pharma, 5 mg/mL, 150 mL bottle, NDC 24478-0323-05
    • Quillivant XR oral powder for suspension, Tris Pharma, 5 mg/mL, 180 mL bottle, NDC 24478-0324-06
    • Quillivant XR oral powder for suspension, Tris Pharma, 5 mg/mL, 60 mL bottle, NDC 24478-0321-02

Updated

Updated May 22, 2019 by Leslie Jensen, PharmD, Drug Information Specialist. Created January 6, 2018 by Michelle Wheeler, PharmD, Drug Information Specialist. © 2019, Drug Information Service, University of Utah, Salt Lake City, UT.

Disclaimer

Drug Shortage Bulletins are copyrighted by the Drug Information Service of the University of Utah and provided by ASHP as its exclusive authorized distributor. ASHP and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, with respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this Bulletin. Neither ASHP nor the University of Utah endorses or recommends the use of any particular drug. Any application of this information for any purpose shall be limited to personal, non-commercial use.

« Back to Drug Shortage Product Bulletins